Literature DB >> 8547662

Distinct temporal patterns of defensin mRNA regulation during drug-induced differentiation of human myeloid leukemia cells.

S Herwig1, Q Su, W Zhang, Y Ma, P Tempst.   

Abstract

Defensins are microbicidal peptides and the principal constituents of neutrophil primary granules. They are presumed to play a prominent role in innate host defenses. We examined defensin mRNA levels during drug-induced differentiation of the promyelocytic leukemia cell line, HL-60. Transcription was restricted to promyelocyte, myelocyte, and very early metamyelocyte stages of the granulocytic pathway. Complete downregulation occurred during late granulocytic maturation or early during phorbol ester-promoted differentiation along the monocyte/macrophage lineage. Retinoic acid (RA) was the strongest inducer of defensin mRNA accumulation, even at doses too low to effect morphologic changes; the initial (first 48 hours), gradual increase resulted from transcriptional activation and was enhanced by granulocyte colony-stimulating factor. In contrast, addition of hybrid polar compounds led to a transient, drug-specific downregulation within the same time period, apparently by means of selectively induced, biphasic degradation of transcripts. Subsequent increase in transcript levels was faster and more pronounced with hexamethylene bisacetamide, relative to dimethyl sulfoxide (DMSO). DMSO-promoted effects were strikingly different in serum-free medium or in the presence of the tyrosine kinase inhibitor, genistein. Under these conditions, and although differentiation was unaffected, early defensin mRNA downregulation was final. The effect did not occur with RA and expression of other myeloid-specific genes was also unchanged. Addition of selected cytokines caused a similar "dip," only at earlier times and uncoupled from differentiation. Tumor necrosis factor-alpha markedly induced defensin levels after 2 days in previously untreated HL-60 cells, but inhibited expression in RA-differentiated cells. These results begin to detail a complex regulation of defensin mRNA synthesis with both spatial and temporal control elements, and a unique modulation by chemical agents, cytokines, and serum-factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8547662

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Regulation of cathelicidin gene expression: induction by lipopolysaccharide, interleukin-6, retinoic acid, and Salmonella enterica serovar typhimurium infection.

Authors:  H Wu; G Zhang; J E Minton; C R Ross; F Blecha
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation.

Authors:  Claudia A Müller; Jasmina Markovic-Lipkovski; Tatjana Klatt; Jutta Gamper; Gerold Schwarz; Hermann Beck; Martin Deeg; Hubert Kalbacher; Susanne Widmann; Johannes T Wessels; Volker Becker; Gerhard A Müller; Thomas Flad
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

3.  Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue.

Authors:  S Krisanaprakornkit; A Weinberg; C N Perez; B A Dale
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  SDF2L1, a component of the endoplasmic reticulum chaperone complex, differentially interacts with {alpha}-, {beta}-, and {theta}-defensin propeptides.

Authors:  Prasad Tongaonkar; Michael E Selsted
Journal:  J Biol Chem       Date:  2008-12-24       Impact factor: 5.157

5.  Complex regulation of human cathelicidin gene expression: novel splice variants and 5'UTR negative regulatory element.

Authors:  Houda Zghal Elloumi; Steven M Holland
Journal:  Mol Immunol       Date:  2007-08-20       Impact factor: 4.407

6.  Antimicrobial activity of HL-60 cells compared to primary blood-derived neutrophils against Staphylococcus aureus.

Authors:  Ragheda Yaseen; Stefanie Blodkamp; Petra Lüthje; Friederike Reuner; Lena Völlger; Hassan Y Naim; Maren von Köckritz-Blickwede
Journal:  J Negat Results Biomed       Date:  2017-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.